Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: A multicenter study

In a retrospective analysis, researchers evaluated outcomes of patients who received CAR T-cell therapy after receiving a bridging regimen with radiotherapy compared with other bridging strategies or no bridging. They found that patients who received radiotherapy bridging had a significant reduction in LDH levels between pre- and post-bridging, which was associated with lower drop-out rates and CAR T toxicity. There was a higher incidence of immune effector cell-associated neurotoxicity syndrome among patients who received chemotherapy bridging. They concluded that radiotherapy might be preferred to other bridging strategies for patients with localized disease or for those with one prevalent symptomatic site.